ClinicalTrials.gg
RecruitingNCT07395206KISOUpdated Mar 3, 2026

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

An interventional study of Digital: Kiso Mind App in Psychosis, Psychotic Disorders and Primary Psychotic Disorders, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Psychotic Disorders with a site in Germany — 19 open to participants now, 21 under way, 4 of them phase 3. Psychotic Disorders · Germany.

Planned enrollment
42nd of 65
60 · median 85
Started
2026
with 5 others
No phase
33 of 72
13 open now
Primary completion
2026-06
later than 8 of 20 live
Registered
69th of 72
by date
Lead sponsor
9 of 72
Charite University, Berlin, Germany

Among the 72 studies in Psychotic Disorders with a site in Germany, this one is the 42nd largest by planned enrollment of the 65 interventional ones that give a count, is one of 6 that started in 2026, is one of 33 with no phase, reaches primary completion later than 8 of the 20 other live ones, and was the 69th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

19 of the 72 studies in Psychotic Disorders with a site in Germany are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Psychotic Disorders with a site in Germany, or all of them as a file.
02

Study summary

The Kiso pilot study is a randomized controlled trial to test the acceptability and feasibility of a novel digital intervention, namely the Kiso Mind smartphone app. A parallel-group design is utilized. Participants either receive access to the Kiso Mind intervention and treatment-as-usual (TAU) in the experimental condition or receive treatment as usual (TAU) in the control condition. The intervention is designed for participants diagnosed with either schizophrenia (F20.0) or schizoaffective disorder (F25.0) according to the ICD-10.

To examine acceptability, feasibility, and preliminary effectiveness, both self-report and rater-based assessments are administered at baseline (T0) and at the end of the 12-week intervention period (post-intervention T1). Lastly, a qualitative interview will be conducted with participants from the experimental condition. The primary outcome of the present study is the acceptability and feasibility of the Kiso Mind app. The secondary outcome consists of general psychopathology, and positive-, negative-, depressive symptoms, as well as social functioning and self-efficacy ratings.

Read the detailed description

There are multiple ways to join the present study. Healthcare workers at different institutions across Germany identify eligible participants and invite them to participate in the study. Those institutions include inpatient wards and outpatient facilities. Moreover, participants can join via multiple channels, including online channels and advertising such as social media, etc. Eligibility screenings and baseline clinician ratings are conducted centrally by research associates (psychologists) at Charité Universitätsmedizin Berlin via a video interview. After confirming the inclusion criteria, participants will be randomised and receive the self-report section of the baseline assessment. Randomization is conducted independently by research associates at the Universitätsklinikum Hamburg-Eppendorf in Hamburg. After 12 weeks, participants complete a clinical interview to assess the rater-based section of the post-treatment assessment and receive the self-report section via email.

All participant data is stored in a pseudonymized format. No clinical data is saved in combination with clinical data. The participants have the right to access their data and the right to claim deletion of their data. Data are stored in an online database, accessible only to researchers involved in the study.

Due to the exploratory nature of this study, we aim to recruit 60 to 80 participants in total until June.

03

Conditions studied

  • Psychosis
  • Psychotic Disorders
  • Primary Psychotic Disorders
  • Schizophrenia Spectrum Disorders
  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • Psychosis
  • Psychotic Disorders
  • Primary Psychotic Disorders
  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophrenia Spectrum Disorders
  • Digital Intervention
  • E-Health
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ICD-10: F20 Schizophrenia, F25 Schizoaffective Disorder
  • Age: 18 - 65 years
  • Sufficient German Language Proficiency
  • Ability to Use a Smartphone

Exclusion criteria

Exclusion Criteria:

  • Intensive Psychotherapy Protocols (more than one psychotherapy session a month)
  • CGI-Score \< 3; > 6
  • No smartphone
  • Neurological Disorders or Brain Damage
  • Acute Suicidality
  • Acute Heavy Substance Abuse or Addiction
  • Current Electroconvulsive Therapy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Digital Intervention (Kiso Mind App) + TAU.

    The intervention comprises a 12-week digital intervention containing several psychoeducation modules as well as a broad variety of evidence-based psychotherapeutic modules based on CBTp principles. In addition, the digital intervention includes functions to assist with daily challenges, such as medication reminders, mood trackers and emergency contacts.

    Behavioral: Digital: Kiso Mind App

  • No intervention
    Treatment as Usual

    with Schizophrenia or Schizoaffective Disorder in Germany consists of quarterly psychiatric appointments for psychopharmacological treatment. Psychotherapy is typically limited to one appointment a month, in very rare cases multiple appointments a month.

Interventions

  • BehavioralDigital: Kiso Mind App

    See above.

06

What researchers measure

Primary outcomes

  1. Proportion of PP receiving threshold dose (Acceptability)

    The proportion of modules completed on average by all participants.

    Time frame: 12 weeks

  2. Nr. of pp willing to participate (Feasibility)

    The number of eligible participants, that are willing to participate in Kiso (recruitment)

    Time frame: 12 weeks

Secondary outcomes

  1. Clinical Global Impression (T0; T1)

    Assesses overall clinical illness severity as judged by the clinician, providing a global rating of the patient's current level of psychopathology. (Scores: 1 to 7; higher scores = higher illness severity)

    Time frame: 12 weeks

  2. Patient Global Impression (T0; T1)

    Description: Assesses overall clinical illness severity as judged by the patients, providing a global rating of the patient's perceived current level of psychopathology. (Scores: 1 to 5; higher scores = higher perceived illness severity)

    Time frame: 12 weeks

  3. Community Assessment of Psychic Experiences (CAPE) (T0, T1)

    Assesses the frequency and distress associated with psychotic-like experiences in the general population, covering positive, negative, and depressive symptom dimensions. (Scores: 0 to 96; higher scores = higher frequency of psychotic-like experiences AND Scores: 0 to 96; higher scores = higher distress of psychotic like experiences)

    Time frame: 12 weeks

  4. Beck Depressions-Inventar (BDI-II) (T0, T1)

    A 21-item self-report questionnaire measuring the severity of depressive symptoms over the past two weeks. (Scores: 0 to 63; higher scores = higher severity of depressive symptoms)

    Time frame: 12 weeks

  5. Brief Symptom Inventory (BSI) (T0, T1)

    A self-report measure assessing general psychological distress across multiple symptom domains (e.g., depression, anxiety, somatization). (Scores: 0 to 212; higher scores = higher self-reported general psychological distress)

    Time frame: 12 weeks

  6. General Self-Efficacy Scale (GSE) (T0, T1)

    Measures perceived self-efficacy, reflecting an individual's belief in their ability to cope with difficult demands and challenges. (Scores: 4 to 40; higher scores = higher self-efficacy)

    Time frame: 12 weeks

  7. Social Functioning Scale (SFS) (T0, T1)

    Assesses social functioning and role performance, including social engagement, interpersonal behavior, and independent living skills.

    Time frame: 12 weeks

  8. EQ-5D Quality of life questionnaire (T0, T1)

    A standardized measure of health-related quality of life, covering mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (Scores: 5 to 25; higher scores = lower health-related quality of life)

    Time frame: 12 weeks

  9. Patient Satisfaction Questionnaire (ZUF-8) (T1, Experimental Group)

    Evaluates patient satisfaction with treatment or services, focusing on perceived quality, usefulness, and overall satisfaction. (Scores: 4 to 28; higher scores = higher patient satisfaction)

    Time frame: 12 weeks

  10. System Usability Scale (SUS) (T1, Experimental Group)

    A 10-item questionnaire assessing perceived usability and user-friendliness of a system or digital intervention.

    Time frame: 12 weeks

  11. Negative Effects Questionnaire (NEQ) (T1, Experimental Group)

    Assesses adverse and unwanted effects of psychological treatment, including symptom worsening, dependency, or emotional distress. (Scores: 0 to 116; higher scores = higher severity of unwanted effects)

    Time frame: 12 weeks

  12. Medication Adherence Report Scale (MARS-5) (T0, T1)

    A self-report measure assessing medication adherence behavior, including intentional and unintentional non-adherence. (Scores: 5 to 25; higher scores = higher medication non-adherence)

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.

Of 460 non-industry interventional studies with no phase under Psychotic Disorders, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 5 months is below that.

Counting every sponsor, half of 462 studies reached it within 34 months; a quarter within 19 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 9, 2026
StartActual
Jan 30, 2026
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395206
Collaborators
Kiso Health GmbH
Responsible party
Kerem Böge (Prof. Dr. Dr., Charite University, Berlin, Germany) — Principal investigator
First posted
Feb 9, 2026
Start date
Jan 30, 2026
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Mar 3, 2026

Study contacts

Pawel Weinstein, M.Sc.
Contact
pawel.weinstein@charite.de
0049 30 450 617 325
Eric Hahn, PD Dr.
Contact
eric.hahn@charite.de
0049 30 450 517 547

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion